Clinical Trial Update: A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction [Phase 4]

View source ↗

Summary

Phase 4 open-label trial comparing ezetimibe, niacin, and colestipol as adjunct therapy for lipid reduction; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• Colestipol (colestipol)
• EZETIMIBE (EZETIMIBE)
• Niacin (nicotinic acid)

Snippet

Sponsor: Tuscaloosa Research & Education Advancement Corporation | Conditions: Hyperlipidemia, Hypercholesterolemia | Phase 4 | Status: COMPLETED | Results posted: 2014-08-12